Clinical Trial Update: Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating carfilzomib in multiple myeloma patients relapsed or refractory to bortezomib has completed Phase 1/Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carfilzomib (carfilzomib)

Snippet

Sponsor: Oncotherapeutics | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED